GlassScriptPhysician profile
Douglas J Woida
NPI 1790823045
$4,808.30
in general payments reported to CMS, 2019-2025
24 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $772 · 2023: $1,095 · 2024: $1,083 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.99 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,160.59 | 2021-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $1,012.30 | 2021-2025 | |
| Lilly USA, LLC | $569.11 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.15 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $306.60 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $254.21 | 2023-2025 | Rexulti, Nuedexta |
| Ironwood Pharmaceuticals, INC | $203.23 | 2022-2024 | Linzess |
| Novo Nordisk INC | $152.01 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $112.41 | 2023-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $90.19 | 2024-2025 | Ponvory |
| Bayer Healthcare Pharmaceuticals INC. | $89.57 | 2024-2025 | |
| Lundbeck LLC | $84.05 | 2024-2025 | Vyepti |
| Ge Healthcare | $75.03 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $52.22 | 2025 | Zoryve |
| Nestle Healthcare Nutrition INC. | $49.52 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $44.81 | 2023-2024 | Rytary |
| Genentech USA, INC. | $44.09 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $41.32 | 2021 | |
| Harmony Biosciences LLC | $20.49 | 2025 | |
| Pfizer INC. | $18.04 | 2025 | |
| Alkermes, INC. | $17.84 | 2021 | |
| Merck Sharp & Dohme LLC | $16.07 | 2021 | |
| Agile Therapeutics, INC. | $13.28 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Woida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.